When evaluating any research peptide supplier, the quality of customer service is as important as product purity—poor communication can signal deeper operational issues.

A Certificate of Analysis (CoA) is supposed to be your primary assurance of peptide quality. Unfortunately, the document itself has become a tool of deception. Spotting red flags has become an essential skill for any researcher or buyer due to fabricated reports, stolen lab data, and "stock purity graphics" that have no connection to the product received.

A Certificate of Analysis (CoA) is a batch-specific analytical record that documents the quality and identity of a research peptide. It is a factual document, not a marketing tool, and should be read critically rather than accepted uncritically.

The Boston-Cambridge metropolitan area represents the densest biomedical research ecosystem globally. Harvard Medical School, the Massachusetts Institute of Technology (MIT), the Broad Institute, Whitehead Institute, Dana-Farber Cancer Institute, and Massachusetts General Hospital all exist within a roughly four-mile radius. This concentration of academic and clinical research institutions, combined with over 500 biotechnology and pharmaceutical companies, creates extraordinary demand for high-purity research reagents—including peptides, antibodies, oligonucleotides, and specialised chemicals.

Mitochondrial dysfunction sits at the crossroads of numerous disease states—from primary mitochondrial myopathies to age-related cardiac and neurologic decline. SS-31 (elamipretide), a synthetic tetrapeptide developed by researchers Szeto and Schiller, represents an approach to directly stabilising mitochondrial function by targeting cardiolipin, a phospholipid unique to the inner mitochondrial membrane .